^
Association details:
| Biomarker: | ER positive + PGR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial
Published date:
05/26/2022
Excerpt:
The Short-HER study randomized 1254 patients with HER2+ early breast cancer to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with anthracycline-taxane chemotherapy. 853 patients with HR+ BC (ER and/or PgR >10%) were included…patients who received AI had a significantly better DFS as compared to patients who received TAM or TAM-AI: 7-yr DFS 87.3% vs 81.7%, log-rank P=0.017 (HR 1.46, 95%CI 1.05-2.03).
Secondary therapy:
Chemotherapy; Aromatase inhibitor
DOI:
10.1200/JCO.2022.40.16_suppl.547
Trial ID:
Source:
Title:
Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer
Excerpt:
...- Estrogen receptor or progesterone receptor positive...
Trial ID:
Source:
Title:
Neo- / adjuvant trial to compare two therapies for patients with high rist breast cancer. Patients will receive either dose-dense the combination EnPC or dose-dense and dose-tailored EC-D (GAIN-2). Neo- / adjuvante Studie zum Vergleich zweier Therapiearme bei Brustkrebs-Patientinnen mit erhöhtem Risiko. Patientinnen erhalten entweder dosisdicht die Kombination EnPC oder dosisdicht und dosisangepasst EC-D.
Excerpt:
...ER/PR positive is defined as ≥ 1% stained cells and HER2 positive is defined as IHC 3+ in > 10% immunoreactive cells or FISH (or equivalent test) ratio ≥ 2.0. ...
Trial ID:
